# Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/EXEL/exelixis-announces-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: EXEL
Company: Exelixis
Source: Exelixis
Published: 2026-05-05 20:05 EST
Original Source URL: https://ir.exelixis.com
## Summary

- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million   - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87   - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2027 - - Conference Call and Webcast Today

## Article Body
- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million   - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87   - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2027 - - Conference Call and Webcast Today
## Recent Company News
- 2026-05-30 14:00 EST — [Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026](https://biopharmsignal.com/news/EXEL/exelixis-announces-results-from-subgroup-analysis-of-phase-3-cabinet-pivotal-trial-evaluating-cabometyxr-cabozantinib-in-non-functional-and-functional-neuroendocrine-tumors-at-asco-2026) — Source: Exelixis
- 2026-05-27 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-june) — Source: Exelixis
- 2026-05-21 21:00 EST — [Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types](https://biopharmsignal.com/news/EXEL/exelixis-announces-presentations-at-asco-2026-highlighting-ongoing-studies-in-diverse-tumor-types) — Source: Exelixis
- 2026-05-19 12:00 EST — [Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer](https://biopharmsignal.com/news/EXEL/exelixis-announces-clinical-development-collaboration-with-merck-for-phase-3-stellar-316-pivotal-trial-for-patients-with-colorectal-cancer) — Source: Exelixis
- 2026-05-07 20:05 EST — [Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May](https://biopharmsignal.com/news/EXEL/exelixis-to-webcast-fireside-chats-as-part-of-upcoming-investor-conferences-in-may) — Source: Exelixis
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)